REDWOOD CITY, Calif.,
Nov. 28, 2016 /PRNewswire/
-- Nevro Corp. (NYSE: NVRO), a global medical device company
that is providing innovative evidence-based solutions for the
treatment of chronic pain, today announced that it has filed a
lawsuit for patent infringement against units of Boston Scientific
(NYSE:BSX). The lawsuit, filed in the United States District
Court for the Northern District of California, asserts that Boston Scientific is
infringing Nevro's patents covering inventions relating to Nevro's
groundbreaking Senza® system and HF10™ therapy. The lawsuit
seeks preliminary and permanent injunctive relief against further
infringement as well as damages and attorney's fees. One of
the asserted patents, U.S. patent no. 8,359,102, was the subject of
two petitions for inter partes review (IPR) filed by Boston
Scientific with the Patent Trial and Appeals Board (PTAB) of the
U.S. Patent and Trademark Office. On November 30, 2015, the PTAB declined to institute
IPRs after finding that Boston Scientific failed to establish a
reasonable likelihood of showing that even one of the challenged
claims of the '102 patent was invalid.
"Nevro was founded in 2006 to develop meaningful advances in the
treatment of chronic pain to improve patients' lives," said
Rami Elghandour, President and CEO
of Nevro. "Intellectual property is the basis for innovation
in health sciences given the long development timelines,
investment, and risk required to bring meaningful advances to
market. We are committed to ensuring continued innovation in
health sciences by protecting our intellectual property."
Documents relating to the lawsuit can be found via registration
at the court's website, www.cand.uscourts.gov. The case no.
is 3:16-cv-06830.
About Nevro
Headquartered in Redwood City,
California, Nevro is a global medical device company focused
on providing innovative products that improve the quality of life
of patients suffering from debilitating chronic pain. Nevro has
developed and commercialized the Senza spinal cord stimulation
(SCS) system, an evidence-based neuromodulation platform for the
treatment of chronic pain. The Senza system is the only SCS system
that delivers Nevro's proprietary HF10 therapy. Senza, HF10, Nevro
and the Nevro logo are trademarks of Nevro.
Investor Relations Contact:
Nevro Investor Relations
Katherine Bock
(650) 433-3247
ir@nevro.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nevro-files-lawsuit-for-patent-infringement-against-boston-scientific-in-the-us-300369262.html
SOURCE Nevro Corp.